BioMarin Pharmaceutical announced that an individual in Germany with severe hemophilia A was treated with ROCTAVIAN, marking the first time that the gene therapy has been given commercially in Europe. Beyond Germany, the company’s applications seeking price and reimbursement approvals and other launch preparation activities continue to progress in France and Italy. In Italy, ROCTAVIAN was awarded conditional innovation designation, which is expected to facilitate pricing and reimbursement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin participates in a conference call with Jefferies
- BioMarin treatment of hypochondroplasia granted FDA orphan status
- BioMarin price target lowered to $108 from $118 at Stifel
- BioMarin raises FY23 non-GAAP EPS view to $1.85-$2.10 from $1.80-$2.05
- BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date